Bimeda® Announces U.S. Launch of Gastrobim™ (Omeprazole) as First and Only FDA-approved Bioequivalent to Gastrogard® (Omeprazole) for Equine Gastric Ulcer Treatment

 Schaumburg, IL — [APR 6, 2026] — Bimeda^®, a global leader in animal health solutions, announced today plans for their U.S. launch of Gastrobim^TM (omeprazole), the first and only FDA-approved bioequivalent to GASTROGARD^® (omeprazole) for the treatment and prevention of recurrence of gastric ulcers in horses and foals 4 weeks of age and older. This approval and roll out represents a major advancement for veterinarians, trainers, and horse owners seeking a clinically equivalent, high-quality option for managing Equine Gastric Ulcer Syndrome (EGUS) in the U.S. Market.

Launched in 2022, Gastrobim has quickly become the fastest-growing omeprazole product in Canada and Europe. Widely adopted and well-reviewed by veterinarians and horse owners, it is recognized for its proven efficacy in treating and healing gastric ulcers, establishing it as a trusted therapeutic option globally.

"We are thrilled to introduce Gastrobim to the U.S. market," said Eric Moore, DVM, Bimeda's Head of Technical Services North America. "Gastric ulcers remain one of the most common and performance-limiting conditions in horses. Offering a bioequivalent, rigorously tested treatment underscores our commitment to supporting equine health, welfare, and performance at an affordable price."

Equine Gastric Ulcer Syndrome affects a significant percentage of performance horses and can lead to reduced appetite, behavioral changes, discomfort, and diminished athletic output. By providing a bioequivalent, apple-flavored alternative to the market, Bimeda aims to expand access to effective treatment and support improved outcomes across the entire equine industry.

Gastrobim will be available soon nationwide through animal health distributors. For more information, visit Gastrobim.com